Semantic Scholar uses AI to extract papers important to this topic.
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL
Background: PBI-1402 reduces the need for transfusion… Expand BACKGROUND: PBI-1402 reduces the need for transfusion and increases hemoglobin (Hb) level and red blood cell count (RBC) in… Expand (-)-Epigallocatechin gallate, (-)-Gossypol; Ad.hIFN-beta, AF-37702, Agatolimod sodium, Agomelatine, Alvocidib hydrochloride, ARC… Expand Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand Background: PBI-1402 is a novel orally active low molecular weight synthetic compound with erythropoiesis stimulating activity… Expand PBI-1402 is a non-toxic, well-defined low molecular weight synthetic hematopoietic growth stimulant. PBI-1402 promotes the… Expand PBI-1402 is an orally active low molecular weight synthetic compound which is currently in a phase Ib/II clinical trial in… Expand Erythropoiesis is regulated by an intricated network of transcription factors and other molecules that mediate differentiation of… Expand The goal of this study was to determine the potential of PBI-1402, a compound that was shown to provide radio- and… Expand Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand